Clinical trials: Diabetic Retinal Disease
Proliferative Diabetic Retinopathy
Study to Assess the Efficacy and Safety of Monthly Octreotide Intramuscular Injections in Patients With Proliferative Diabetic Retinopathy After Lasercoagulation This Study is Not Being Conducted in the United States.
Phase III study comparing monthly octreotide i.m. in comparison to no additional treatment in patients with proliferative diabetic retinopathy after lasercoagulation.
- Trial name
- NCT00170742
- Testing
- Octreotide, 30 mg i.m. LAR formulation
- Where
- Switzerland
- Volunteers
- 17 people
- Sponsor
- Novartis
Diabetes, Diabetes Mellitus
Discovering Early Biomarkers in Circulating Endothelial Cells for Diabetes Complications by Single Cell RNA Sequencing
The purpose of this study is to discover early biomarkers in circulating endothelial cells for diabetes complications, by investigating circulating endothelial cells in blood samples from patients with newly diagnosed…
- Conditions
- Diabetes, Diabetes Mellitus, Proliferative Diabetic Retinopathy, Diabetic Maculopathy
- Trial name
- CEC4DC (NCT05169502)
- Where
- Denmark
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Aarhus University Hospital
Cystoid Macular Edema
Macugen to Prevent Worsening of Macular Edema Following Cataract Surgery in Diabetics
This research is being conducted to look at the effects of an intraocular drug (pegaptanib, also called Macugen) for the treatment of swelling in the retina (the light sensitive tissue in the back of the eye) that often occurs…
- Trial name
- NCT00346983
- Testing
- Pegaptanib sodium, Control
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Johns Hopkins University
Proliferative Diabetic Retinopathy (PDR)
Early Vitrectomy vs PRP in Early Proliferative Diabetic Retinopathy
The goal of this clinical trial is to learn whether early microincision vitrectomy surgery (MIVS) can improve retinal neovascularization outcomes compared to standard pan-retinal photocoagulation (PRP) in patients with early…
- Trial name
- NCT07586787
- Testing
- Microincision Vitrectomy Surgery, Panretinal Photocoagulation
- Where
- 6 sites in China
- Volunteers
- 100 people
- Sponsor
- Xiamen Ophthalmology Center Affiliated to Xiamen University
Diabetes, Diabetic Retinopathy
Retinal Blood Flow and Microthrombi in Type 1 Diabetes
The project aims to find mechanisms for the abnormal retinal blood flow that in diabetic patients often precedes any evidence of clinical retinopathy and may contribute to the development of retinopathy.
- Trial name
- NCT00406991
- Testing
- aspirin, clopidogrel
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Schepens Eye Research Institute
Macular Edema, Diabetic
A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema
The study hypothesis under test is that administration of the CCR2/5 antagonist has the potential to be as effective as the current treatment options for subjects with diabetic macular edema.
- Trial name
- NCT01994291
- Testing
- Ranibizumab, PF-04634817
- Where
- 63 sites in United States, Bulgaria and 7 more
- Volunteers
- 199 people
- Sponsor
- Pfizer
Type 1 Diabetes
DIabetic Retinopathy Candesartan Trials.
The primary objective is to determine whether candesartan, compared to placebo reduces the progression of diabetic retinopathy in normotensive, normoalbuminuric type 1 diabetic patients with retinopathy.
- Trial name
- DIRECT (NCT00252720)
- Testing
- candesartan
- Volunteers
- 1,850 people
- Sponsor
- AstraZeneca
Diabetic Macular Edema
A Comparison of Standard Laser With Micropulse Laser for the Treatment of Diabetic Macular Oedema.
DIAMONDS is a Randomised Controlled Clinical Trial that is being carried out in the UK to determine the clinical effectiveness and cost-effectiveness of micropulse laser, compared with standard laser, for the treatment of…
- Trial name
- DIAMONDS (NCT03690050)
- Testing
- Diode 577 nm subthreshold micropulse laser, Standard threshold laser (532 nm laser)
- Where
- 14 sites in United Kingdom
- Volunteers
- 266 people
- Sponsor
- Belfast Health and Social Care Trust
Type2 Diabetes, Diabetic Retinopathy
Tangningtongluo Tablet in the Treatment of Non-proliferative Diabetic Retinopathy
This trial is planned to collect relevant clinical data to evaluate the prevention efficacy and safety of Tangningtongluo tablets on the non-proliferation period of diabetic retinopathy.
- Trial name
- NCT05007262
- Testing
- Tangningtongluo tablets, Calcium dobesilate capsules
- Where
- 13 sites in China
- Volunteers
- 240 people
- Sponsor
- Guizhou Bailing Group Pharmaceutical Co Ltd
Depression, Age-related Macular Degeneration
Effect of a Self-care Intervention on Depression in People With Age-related Macular Degeneration or Diabetic Retinopathy
The purpose of this trial is to determine the short-term effect of a self-care intervention on depression in patients with age-related macular degeneration or diabetic retinopathy.
- Trial name
- NCT02261194
- Testing
- Self-Care Tools
- Where
- Canada
- Volunteers
- 80 people
- Sponsor
- Maisonneuve-Rosemont Hospital
Proliferative Diabetic Retinopathy - High Risk
Patient Comfort Using Green vs. Yellow Pan Retinal Photocoagulation
Our aim is to compare patient comfort when using the 532 nanometer (green) wavelength laser to the 577 nanometer (yellow) wavelength laser during pan retinal photocoagulation to treat patients with diabetic retinopathy.
- Trial name
- NCT02995629
- Testing
- laser indirect ophthalmoscopy pan retinal photocoagulation
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Wills Eye
Diabetic Retinopathy
OCT Biomarkers for Diabetic Retinopathy
Diabetic retinopathy (DR) is caused by changes in the blood vessels of the retina associated with long-term Type 1 or Type 2 diabetes mellitus. DR is a leading cause of blindness in the United States.
- Trial name
- NCT02330042
- Where
- United States
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- Oregon Health and Science University
Diabetic Macular Edema (DME)
Safety, Tolerability and Evidence of Activity Study of UBX1325 in Patients With Diabetic Macular Edema (BEHOLD)
This study is intended to assess the exposure, safety, biological activity, and durability of UBX1325, a phosphate pro-drug, and its active parent molecule (UBX0601) following a single intravitreal (IVT) injection of UBX1325 in…
- Trial name
- NCT04857996
- Testing
- UBX1325
- Where
- 22 sites in United States, Canada
- Volunteers
- 65 people
- Sponsor
- Unity Biotechnology, Inc.
Diabetic Retinopathy, Diabetic Eye Problems
Detection and Classification of Diabetic Retinopathy From Posterior Pole Images With A Deep Learning Model
The duration of diabetes is directly related to eye complications. Diabetic retinopathy affects 80 percent of those who have had diabetes for 20 years or more.
- Conditions
- Diabetic Retinopathy, Diabetic Eye Problems, Diabetic Macular Edema
- Trial name
- NCT04805541
- Testing
- Color Fundus Photography, Mydriatic Agent, EyeCheckup - AI Based DR Screening
- Where
- Turkey (Türkiye)
- Volunteers
- 900 people
- Sponsor
- Ural Telekomunikasyon Sanayi Ticaret Anonim Sirketi
Macular Edema
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2798745 in Participants With Diabetic Macular Edema
The study will be composed of 3 periods for all participants: Screening, 28-day Treatment period, and Follow-up visit (approximately 28 days after the final dose).
- Trial name
- NCT04292912
- Testing
- GSK2798745
- Where
- 11 sites in United States, Australia and 1 more
- Volunteers
- 16 people
- Sponsor
- GlaxoSmithKline
Diabetic Macular Edema
Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema
The primary objectives of this study were to evaluate the safety and efficacy of LKA651 in patients with macular edema from diabetic macular edema (DME),
- Trial name
- NCT03927690
- Testing
- LKA651, Lucentis
- Where
- 22 sites in United States, Germany and 3 more
- Volunteers
- 91 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Retinopathy, Lasers
Pattern Scanning Laser Pan-retinal Photocoagulation in Proliferative Diabetic Retinopathy
A randomized study to assess the safety and efficacy of single-session pan-retinal photocoagulation (PRP) using Pattern Scan Laser (PASCAL) in proliferative diabetic retinopathy (PDR) - 1,700 shots vs 2,500 shots
- Conditions
- Diabetic Retinopathy, Lasers, Treatment Outcome
- Trial name
- NCT02816073
- Testing
- Pan-retinal photocoagulation using pattern scanning laser
- Volunteers
- 17 people
- Sponsor
- United Christian Hospital
Age-Related Macular Degeneration, Diabetic Maculopathy
Selective RPE Laser Treatment (SRT) for Various Macular Diseases
In this prospective clinical study SRT is performed with various pulse durations at 1.7µs and additionally 200ns to evaluate the different clinical effects of both laser regimens.
- Conditions
- Age-Related Macular Degeneration, Diabetic Maculopathy, Central Serous Chorioretinopathy
- Trial name
- NCT00403884
- Testing
- Selective RPE laser treatment
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- University of Regensburg
Non Proliferative Diabetic Retinopathy
Pars-plana Vitrectomy vs Panretinal Photocoagulation for Severe NPDR
It is estimated that there are about 600 million diabetes mellitus (DM) patients all over the world until 2040，and almost 50% of whom have some degree of diabetic retinopathy (DR) at any given time.
- Trial name
- NCT04103671
- Testing
- Prompt panretinal photocoagulation, 25G Pars-plana vitrectomy
- Where
- China
- Volunteers
- 272 people
- Sponsor
- Zhongshan Ophthalmic Center, Sun Yat-sen University
Proliferative Diabetic Retinopathy
Vitrous Analysis in Proliferative Diabetic Retinopathy
Analysis of vitreous proteins in patients undergoing pars plana vitrectomy for proliferative diabetic retinopathy
- Trial name
- NCT01478763
- Where
- Sweden
- Volunteers
- 200 people
- Sponsor
- Anders Kvanta
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.